Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marco Favaro is active.

Publication


Featured researches published by Marco Favaro.


Antimicrobial Agents and Chemotherapy | 2002

New Site of Modification of 23S rRNA Associated with Clarithromycin Resistance of Helicobacter pylori Clinical Isolates

Carla Fontana; Marco Favaro; Silvia Minelli; Anna Angela Criscuolo; Antonio Pietroiusti; Alberto Galante; Cartesio Favalli

ABSTRACT Resistance of Helicobacter pylori to clarithromycin occurs with a prevalence ranging from 0 to 15%. This has an important clinical impact on dual and triple therapies, in which clarithromycin seems to be the better choice to achieve H. pylori eradication. In order to evaluate the possibility of new mechanisms of clarithromycin resistance, a PCR assay that amplified a portion of 23S rRNA from H. pylori isolates was used. Gastric tissue biopsy specimens from 230 consecutive patients were cultured for H. pylori isolation. Eighty-six gastric biopsy specimens yielded H. pylori-positive results, and among these 12 isolates were clarithromycin resistant. The latter were studied to detect mutations in the 23S rRNA gene. Sequence analysis of the 1,143-bp PCR product (portion of the 23S rRNA gene) did not reveal mutation such as that described at position 2142 to 2143. On the contrary, our findings show, for seven isolates, a T-to-C transition at position 2717. This mutation conferred a low level of resistance, equivalent to the MIC for the isolates, selected using the E-test as well as using the agar dilution method: 1 μg/ml. Moreover, T2717C transition is located in a highly conserved region of the 23S RNA associated with functional sites: domain VI. This fact has a strong effect on the secondary structure of the 23S RNA and on its interaction with macrolide. Mutation at position 2717 also generated an HhaI restriction site; therefore, restriction analysis of the PCR product also permits a rapid detection of resistant isolates.


Journal of Clinical Microbiology | 2005

Use of the MicroSeq 500 16S rRNA Gene-Based Sequencing for Identification of Bacterial Isolates That Commercial Automated Systems Failed To Identify Correctly

Carla Fontana; Marco Favaro; Marco Pelliccioni; Enrico Salvatore Pistoia; Cartesio Favalli

ABSTRACT Reliable automated identification and susceptibility testing of clinically relevant bacteria is an essential routine for microbiology laboratories, thus improving patient care. Examples of automated identification systems include the Phoenix (Becton Dickinson) and the VITEK 2 (bioMérieux). However, more and more frequently, microbiologists must isolate “difficult” strains that automated systems often fail to identify. An alternative approach could be the genetic identification of isolates; this is based on 16S rRNA gene sequencing and analysis. The aim of the present study was to evaluate the possible use of MicroSeq 500 (Applera) for sequencing the 16S rRNA gene to identify isolates whose identification is unobtainable by conventional systems. We analyzed 83 “difficult” clinical isolates: 25 gram-positive and 58 gram-negative strains that were contemporaneously identified by both systems—VITEK 2 and Phoenix—while genetic identification was performed by using the MicroSeq 500 system. The results showed that phenotypic identifications by VITEK 2 and Phoenix were remarkably similar: 74% for gram-negative strains (43 of 58) and 80% for gram-positive strains were concordant by both systems and also concordant with genetic characterization. The exceptions were the 15 gram-negative and 9 gram-positive isolates whose phenotypic identifications were contrasting or inconclusive. For these, the use of MicroSeq 500 was fundamental to achieving species identification. In clinical microbiology the use of MicroSeq 500, particularly for strains with ambiguous biochemical profiles (including slow-growing strains), identifies strains more easily than do conventional systems. Moreover, MicroSeq 500 is easy to use and cost-effective, making it applicable also in the clinical laboratory.


BMC Infectious Diseases | 2009

Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options

Silvia Natoli; Carla Fontana; Marco Favaro; Alberto Bergamini; Gian Piero Testore; Silvia Minelli; Maria Cristina Bossa; Mauro Casapulla; Giorgia Broglio; Angela Beltrame; Laura Cudillo; Raffaella Cerretti; Francesca Leonardis

BackgroundCoagulase-negative staphylococci (CoNS) are a major cause of nosocomial blood stream infection, especially in critically ill and haematology patients. CoNS are usually multidrug-resistant and glycopeptide antibiotics have been to date considered the drugs of choice for treatment. The aim of this study was to characterize CoNS with reduced susceptibility to glycopeptides causing blood stream infection (BSI) in critically ill and haematology patients at the University Hospital Tor Vergata, Rome, Italy, in 2007.MethodsHospital microbiology records for transplant haematology and ICU were reviewed to identify CoNS with elevated MICs for glycopeptides, and isolates were matched to clinical records to determine whether the isolates caused a BSI. The isolates were tested for susceptibility to new drugs daptomicin and tigecycline and the genetic relationship was assessed using f-AFLP.ResultsOf a total of 17,418 blood cultures, 1,609 were positive for CoNS and of these, 87 (5.4%) displayed reduced susceptibility to glycopeptides. Clinical review revealed that in 13 cases (7 in haematology and 6 in ICU), CoNS with reduced susceptibility to glycopeptides were responsible for a BSI. Staphylococcus epidermidis was the causative organism in 11 instances and Staphylococcus haemolyticus in 2. The incidence of oxacillin resistance was high (77%), although all isolates remained susceptible to linezolid, daptomycin and tigecycline. Fingerprinting of CoNS identified one clonal relationship between two isolates.ConclusionMulti-resistant CoNS with reduced susceptibility to glycopeptides, although still relatively infrequent in our hospital, are emerging pathogens of clinical concern. Surveillance by antibiotyping with attention to multi-resistant profile, and warning to clinicians, is necessary.


BMC Infectious Diseases | 2008

Acinetobacter baumannii in intensive care unit: A novel system to study clonal relationship among the isolates

Carla Fontana; Marco Favaro; Silvia Minelli; Maria Cristina Bossa; Gian Piero Testore; Francesca Leonardis; Silvia Natoli; Cartesio Favalli

BackgroundThe nosocomial infections surveillance system must be strongly effective especially in highly critic areas, such as Intensive Care Units (ICU). These areas are frequently an epidemiological epicentre for transmission of multi-resistant pathogens, like Acinetobacter baumannii. As an epidemic outbreak occurs it is very important to confirm or exclude the genetic relationship among the isolates in a short time. There are several molecular typing systems used with this aim. The Repetitive sequence-based PCR (REP-PCR) has been recognized as an effective method and it was recently adapted to an automated format known as the DiversiLab system.MethodsIn the present study we have evaluated the combination of a newly introduced software package for the control of hospital infection (VIGI@ct) with the DiversiLab system. In order to evaluate the reliability of the DiversiLab its results were also compared with those obtained using f-AFLP.ResultsThe combination of VIGI@ct and DiversiLab enabled an earlier identification of an A. baumannii epidemic cluster, through the confirmation of the genetic relationship among the isolates. This cluster regards 56 multi-drug-resistant A. baumannii isolates from several specimens collected from 13 different patients admitted to the ICU in a ten month period. The A. baumannii isolates were clonally related being their similarity included between 97 and 100%. The results of the DiversiLab were confirmed by f-AFLP analysis.ConclusionThe early identification of the outbreak has led to the prompt application of operative procedures and precautions to avoid the spread of pathogen. To date, 6 months after the last A. baumannii isolate, no other related case has been identified.


Journal of Clinical Microbiology | 2003

Detection of clarithromycin-resistant Helicobacter pylori in stool samples.

Carla Fontana; Marco Favaro; Antonio Pietroiusti; Enrico Salvatore Pistoia; Alberto Galante; Cartesio Favalli

ABSTRACT The recognition of the role of Helicobacter pylori in gastric diseases has led to the widespread use of antibiotics in the eradication of this pathogen. The most advocated therapy, triple therapy, often includes clarithromycin. It is well known that clarithromycin resistance is one of the major causes of eradication failure. The development of a rapid noninvasive technique that could easily be performed on fecal samples and that could also provide information about the antibiotic resistance of this microorganism is therefore advisable. Previous findings have demonstrated that clarithromycin resistance is due to a single point mutation in the 23S rRNA. All the mutations described have been associated with specific restriction sites, namely BsaI (A2143G), MboII (A2142C/G), and HhaI (T2717C). On this basis we have developed a new method, a seminested PCR, allowing screening for clarithromycin resistance of H. pylori directly on stool samples. This method furnished a 783-bp fragment of the 23S rRNA, which was subsequently digested by MboII, BsaI, and HhaI, in order to identify single point mutations associated with clarithromycin resistance. Of a total of 283 stool samples examined, 125 were H. pylori positive and two of them were shown to contain clarithromycin-resistant strains due to the presence of a mutation at position 2717, whereas no PCR products contained mutations at position 2142 or 2143. In order to evaluate the reliability of the new system, we compared the results of restriction analysis of the PCR products with the MICs shown by the H. pylori isolates by culturing gastric biopsies from the same patients.


BMC Research Notes | 2010

Emergence of KPC-producing Klebsiella pneumoniae in Italy

Carla Fontana; Marco Favaro; Loredana Sarmati; Silvia Natoli; Anna Altieri; Maria Cristina Bossa; Silvia Minelli; Francesca Leonardis; Cartesio Favalli

BackgroundThe emergence of KPC-producing K. pneumoniae has now become a global concern. KPC beta-lactamases are plasmid-borne and, like extended spectrum beta lactamases (ESBLs), can accumulate and transfer resistance determinants to other classes of antibiotics. Therefore, infection control guidelines on early identification and control of the spread of organisms carrying these resistant determinants are needed.FindingsKlebsiella pneumoniae carbapenemase (KPC) was detected in two isolates of carbapenem-resistant K. pneumoniae obtained from patients at an Italian teaching hospital. The first strain was isolated from a culture drawn from a central venous device (CVC) in a patient with Crohns disease who was admitted to a gastroenterology ward. The second was isolated from a urine sample collected from an indwelling urinary catheter in an intensive care unit (ICU) patient with a subdural haematoma. The patients had not travelled abroad. Both isolates were resistant to all β-lactams and were susceptible to imipenem and meropenem but resistant to ertapenem. Isolates also showed resistance to other classes of non-β-lactam antibiotics, such as quinolones, aminoglycosides (with the exception for amikacin), trimethoprim-sulfamethoxazole (TMP-SMX) and nitrofurantoin. They were determined to contain the plasmid encoding the carbapenemase gene bla-KPC and were also positive in the Hodge test.ConclusionsThis is the second report of KPC-producing isolates in Italy, but the first concerning KPC type 2 gene, and it may have important implications for controlling the transmission of microorganisms resistant to antibiotics.


Journal of Hospital Infection | 2009

Bacillus cereus heteroresistance to carbapenems in a cancer patient

Vincenzo Savini; Marco Favaro; Carla Fontana; Chiara Catavitello; Andrea Balbinot; Marzia Talia; Fabio Febbo; Domenico D'Antonio

1. Posfay-Barbe KM, Zerr DM, Pittet D. Infection control in paediatrics. Lancet 2008;8:19e31. 2. Pittet D, Allegranzi B, Storr J, et al. Infection control as a major World Health Organization priority for developing countries. J Hosp Infect 2008;68:285e92. 3. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, editor. Hospital Epidemiology and Infection Control. 3rd edn. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1659e702. 4. World Health Organization. Global database on child growth and malnutrition: the Z-score or standard deviation system. Document WHO/NUT/97.4. Geneva: World Health Organization; 1997. 5. Moreira LL, Netto EM, Nascimento-Carvalho CM. Risk factors for nosocomial rotavirus infection in a paediatric hospital: the potential role for rotavirus use. Vaccine, doi:10.1016/j.vaccine.2008.10.074. 6. Muhlemann K, Franzini C, Aebi C, et al. Prevalence of nosocomial infections in Swiss children’s hospitals. Infect Control Hosp Epidemiol 2004;25:765e71. 7. Tabone MD, Vu Thien H, Moissenet D, Leverger G. Nosocomial infections in immnocompromised children. Pathol Biol (Paris) 2000;48:893e900.


Microbes and Infection | 2012

Tuberculosis-like pneumonias by the aerobic actinomycetes Rhodococcus, Tsukamurella and Gordonia

Vincenzo Savini; Paolo Fazii; Marco Favaro; Daniela Astolfi; Ennio Polilli; Arianna Pompilio; Mariangela Vannucci; Claudio D’Amario; Giovanni Di Bonaventura; Carla Fontana; Domenico D’Antonio

The order Actinomycetales includes phylogenetically diverse but morphologically similar aerobic and anaerobic organisms, exhibiting filamentous branching structures which fragment into rods or coccoid forms. Lung pathogens of the order comprise Mycobacterium, Nocardia, Corynebacterium, Actinomyces, Kytococcus, Rothia, Williamsia, as well as Gordonia, Tsukamurella and Rhodococcus. Particularly, members of the last three genera are uncommon aerobic agents of lung cavitations and tuberculosis(TB)-like syndromes, that should be carefully considered in the aetiology of parenchymal lesions. Correct identification of such organisms is hard to obtain, but is crucial to provide patients with adequate diagnose and treatment. Then, this review aims to unearth their airway tropism, as well as their clinical impact as agents of lung disease.


Journal of Medical Case Reports | 2008

Diagnostic difficulties of Lactobacillus casei bacteraemia in immunocompetent patients: A case report

Chiara Tommasi; Francesco Equitani; Marcello Masala; Milva Ballardini; Marco Favaro; Marcello Meledandri; Carla Fontana; Pasquale Narciso; Emanuele Nicastri

IntroductionLactobacilli are currently proposed as probiotic agents in several dietary products. In blood cultures, they are usually considered as contaminants, but in recent years they have been recognized as causal infectious agents of endocarditis, urinary tract infections, meningitis, intra-abdominal infections and bacteraemia.Case presentationWe report a case of Lactobacillus casei bacteraemia in a 66-year-old immunocompetent man with a history of fever of unknown origin. Leuconostoc bacteraemia was demonstrated by blood culture, but a later polymerase chain reaction analysis with sequencing of 16S ribosomal RNA identified Lactobacillus casei and a successful antibiotic therapy was performed.ConclusionBacteraemia caused by probiotic organisms is rare but underestimated, since they are normally regarded as contaminants and their role as primary invaders is not always easily established. Although the consumption of probiotic products cannot be considered a risk factor in the development of diseases caused by usually non-pathogenic bacteria, specific individual clinical histories should be taken into account. This report should alert both clinicians and microbiologists to the possibility of unusual pathogens causing serious illnesses and to the use of 16S ribosomal RNA sequencing for molecular identification as a powerful tool in confirming the diagnosis of infrequent pathogens.


Journal of Clinical Microbiology | 2008

Multidrug-Resistant Escherichia fergusonii: a Case of Acute Cystitis

Vincenzo Savini; Chiara Catavitello; Marzia Talia; Assunta Manna; Franca Pompetti; Marco Favaro; Carla Fontana; Fabio Febbo; Andrea Balbinot; Fabio Di Berardino; Giovanni Di Bonaventura; Silvia Di Zacomo; Francesca Esattore; Domenico D'Antonio

ABSTRACT We report a case in which Escherichia fergusonii, an emerging pathogen in various types of infections, was associated with cystitis in a 52-year-old woman. The offending strain was found to be multidrug resistant. Despite in vitro activity, beta-lactam treatment failed because of a lack of patient compliance with therapy. The work confirms the pathogenic potential of E. fergusonii.

Collaboration


Dive into the Marco Favaro's collaboration.

Top Co-Authors

Avatar

Carla Fontana

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Cartesio Favalli

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Silvia Natoli

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Domenico D'Antonio

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Loredana Sarmati

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Gian Piero Testore

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pasquale Sordillo

University of Rome Tor Vergata

View shared research outputs
Researchain Logo
Decentralizing Knowledge